Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Irritable Bowel Syndrome With Diarrhea (IBS-D) Clear all

Conditions: Irritable Bowel Syndrome
Interventions: 250 mg LX1033 tablets, Placebo tablet; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 81
States / cities: Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more

Conditions: Irritable Bowel Syndrome
Interventions: DNK333; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 29
States / cities: Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Serum-Derived Bovine Immunoglobulin, Placebo; Dietary Supplement · Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, Camlipixant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 112
States / cities: Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 91 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: BEKINDA, Placebo; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Asimadoline, Placebo; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 142
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome
Interventions: EnteraGam; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more

Conditions: Irritable Bowel Syndrome
Interventions: Blautix, Placebo; Biological · Other
Lead sponsor: 4D pharma plc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: CIN-103, Placebo; Drug
Lead sponsor: CinPhloro Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more

Conditions: Diarrhea-predominant Irritable Bowel Syndrome
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI); Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: ASP7147, Placebo; Drug
Lead sponsor: Seldar Pharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Encino, California • La Mesa, California + 9 more

Conditions: Irritable Bowel Syndrome
Interventions: DDP225; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: DNK333, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 180 participants
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Fecal Incontinence, Irritable Bowel Syndrome With Diarrhea
Interventions: Psyllium; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Rezular 15mg, Placebo, Rezular; Drug
Lead sponsor: AGI Therapeutics, Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Wilmington, North Carolina

Search by objective public record fields.

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Retrospective Study of IBS-D Patients Previously Receiving SBI

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

The Role of Fiber in the Prevention and Treatment of Fecal Incontinence

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)